Pathogenetic pathways in nonalcoholic fatty liver disease: An incomplete Jigsaw puzzle
Nonalcoholic fatty liver disease (NAFLD) is characterized by excess liver fat infiltration
(steatosis in 5% of hepatocytes) in the absence of significant alcohol consumption or other …
(steatosis in 5% of hepatocytes) in the absence of significant alcohol consumption or other …
Nanoformulations for the Diagnosis and Treatment of Metabolic Dysfunction-associated Steatohepatitis
X Qin, J Liu - Acta Biomaterialia, 2024 - Elsevier
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive phase of
metabolic dysfunction-associated steatotic liver disease (MASLD) that develops into …
metabolic dysfunction-associated steatotic liver disease (MASLD) that develops into …
Investigation about the correlation between the severity of metabolic-associated fatty liver disease and adherence to the Mediterranean diet
M Mokhtare, A Abdi, AM Sadeghian… - Clinical Nutrition …, 2023 - Elsevier
Background Metabolic-associated fatty liver disease (MAFLD) is defined by fatty liver
combined with a disturbed metabolic state. Mediterranean diet (MedDiet) contains anti …
combined with a disturbed metabolic state. Mediterranean diet (MedDiet) contains anti …
[HTML][HTML] Prevalence and crucial parameters in diabesity-related liver fibrosis: a preliminary study
S Suwała, A Białczyk, K Koperska, A Rajewska… - Journal of Clinical …, 2023 - mdpi.com
Diabetes and obesity have been recognized as confirmed risk factors for the occurrence of
liver fibrosis. Despite the long-standing acknowledgment of “diabesity”, the simultaneous …
liver fibrosis. Despite the long-standing acknowledgment of “diabesity”, the simultaneous …
[HTML][HTML] Community-centered disease severity assessment of metabolic dysfunction-associated fatty liver disease
JF Huang, PC Tsai, ML Yeh, CF Huang… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Methods This multicenter cross-sectional study enrolled adults participating in liver disease
screening in the community. Patients were stratified following MAFLD diagnostic criteria, to …
screening in the community. Patients were stratified following MAFLD diagnostic criteria, to …
Simple proxies of insulin resistance identify obese metabolic dysfunction‐associated fatty liver disease subjects with advanced liver disease
G Petralli, A Salvati, D Tricò, G Ricco… - Diabetes/Metabolism …, 2024 - Wiley Online Library
Aims Insulin resistance (IR) plays a pivotal role in the pathogenesis of Metabolic dysfunction‐
Associated Fatty Liver Disease (MAFLD), which can progress to liver fibrosis. We examined …
Associated Fatty Liver Disease (MAFLD), which can progress to liver fibrosis. We examined …
[HTML][HTML] Metabolic puzzle: Exploring liver fibrosis differences in Asian metabolic-associated fatty liver disease subtypes
SS Shaikh, FA Qazi-Arisar, S Nafay… - World Journal of …, 2024 - ncbi.nlm.nih.gov
BACKGROUND Metabolic-associated fatty liver disease (MAFLD) is a liver condition marked
by excessive fat buildup in the absence of heavy alcohol use. It is primarily linked with …
by excessive fat buildup in the absence of heavy alcohol use. It is primarily linked with …
[HTML][HTML] Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study
AY Arslan, S Celik, F Amin, I Caylak, I Kesapli… - Hepatology …, 2024 - ncbi.nlm.nih.gov
Materials and Methods We performed a retrospective analysis of prospectively collected
data from February 1, 2022, to April 14, 2023, at a Family Medicine Outpatient Clinic. The …
data from February 1, 2022, to April 14, 2023, at a Family Medicine Outpatient Clinic. The …
[HTML][HTML] Investigating peripheral blood monocyte and T-cell subsets as non-invasive biomarkers for asymptomatic hepatic steatosis: results from the Multi-Ethnic Study …
RW Niedecker, JA Delaney, MF Doyle… - Frontiers in …, 2024 - frontiersin.org
Background Circulating immune cells have gained interest as biomarkers of hepatic
steatosis. Data on the relationships between immune cell subsets and early-stage steatosis …
steatosis. Data on the relationships between immune cell subsets and early-stage steatosis …
Lusianthridin ameliorates high fat diet-induced metabolic dysfunction-associated fatty liver disease via activation of FXR signaling pathway.
X Tang, Q Liao, Q Li, L Jiang, W Li, J Xu, A Xiong… - European Journal of …, 2024 - Elsevier
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common chronic liver
disease, but there are few specific medications for it. Lusianthridin, a major phenanthrene …
disease, but there are few specific medications for it. Lusianthridin, a major phenanthrene …